PI maintains aggressive price target on Nobilis Health after CEO resignation

A shakeup at the top of Nobilis Health (Nobilis Health Stock Quote, Chart, News: TSX:NHC) isn’t shaking PI Financial analyst Sheila Broughton’s faith in the company.

In a research update to clients this morning, Broughton maintained her “Buy” rating and one year target price of (U.S.) $9.50 on Nobilis.

This morning, Nobilis announced that its current executive chairman of the board of directors of the company, Harry Fleming, will become CEO of the company, effective immediately. The company said Chris Lloyd has resigned as CEO of the company, effective Jan. 6, 2016.

“The company appreciates the hard work Chris has performed for the company in 2015 and wishes him the best of luck in his new endeavours,” said Fleming. “The management team is excited to roll out its plans for 2016 which will continue the growth and innovation we have displayed in the past three years. With our third quarter financials close to release we will be able to articulate our plans in more detail in the very near future.”

Broughton thinks the reasons behind the news are of a personal nature.

“Nobilis surprised the street with the announcement of Mr. Lloyd’s resignation in advance of the release of Q315 results,” she says. “We believe the turmoil and stress of events this fall and their impact on Mr. Lloyd’s health were material in his resignation. Nobilis and Mr. Lloyd have signed a formal separation agreement and there are no legal disagreements / lawsuits. Mr. Lloyd stated he is not selling his shares.”

Broughton thinks Nobilis’s Q3, 2015 results are now “imminent”. She also believes there are several near-term catalysts for the company, including the release of the restated 2014, Q115 and Q215 financials, the release of the Q3, 2015 financials, and the pre-release of the Q4, 2015 revenue, noting that the company has guided full year revenue of (U.S.) $233-million.

Shares of Nobilis Health on the NYSEMKT closed today down 20.3 per cent to $2.47.

More Cantech Life Sciences

Tagged with: nhc
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

This investor loves Trane Technologies

Black Swan Dexteritas president and portfolio manager Kim Bolton said Trane Technologies (Trane Technologies Stock Quote, Chart, News, Analysts, Financials… [Read More]

6 hours ago

This analyst just upgraded Roblox

Roth Capital Markets analyst Eric Handler upgraded Roblox (Roblox Stock Quote, Chart, News, Analysts, Financials NYSE:RBLX) to “Buy” from “Neutral”… [Read More]

7 hours ago

Is Computer Modelling Group stock a buy?

Ventum Capital Markets analyst Amr Ezzat maintained a “Buy” rating and C$7.50 price target on Computer Modelling Group (Computer Modelling… [Read More]

7 hours ago

This Canadian tech stock is a buy, Beacon Securities says

Beacon Securities analyst Donangelo Volpe reiterated a “Buy” rating on Haivision Systems (Haivision Systems Stock Quote, Chart, News, Analysts, Financials… [Read More]

10 hours ago

Should you sell your OpenText stock?

OpenText (OpenText Stock Quote, Chart, News, Analysts, Financials NASDAQ:OTEX) reported fiscal second-quarter results on Feb. 5 that RBC Capital Markets… [Read More]

1 day ago

Lightspeed is a wait-and-see stock, ATB says

ATB Capital Markets analyst Martin Toner maintained a “Sector Perform” rating on Lightspeed Commerce (Lightspeed Commerce Stock Quote, Chart, News,… [Read More]

1 day ago